A scientific rationale for protective therapy in Parkinson's disease

  • C. W. Olanow
Full Papers


The desire to introduce neuroprotective therapy for Parkinson's disease has begun to focus attention on pathogenetic mechanisms responsible for cell death. Considerable theory and some evidence have now accumulated to suggest that factors related to oxidative stress, mitochondrial bioenergetic defects, excitatory neurotoxicity, calcium cytotoxicity, and trophic factor deficiencies acting either singularly or in combination may contribute to the development of cell death in Parkinson's disease. A better understanding of the specific pathogenetic mechanism involved in cell degeneration might provide a scientific basis for testing a putative neuroprotective therapy. This chapter reviews the theory and evidence in support of these different mechanisms and possible strategies that might provide neuroprotection and interfere with the natural progression of Parkinson's disease.


Neuroprotection neurodegeneration Parkinson's disease oxidative stress 


  1. Aebischer P, Winn SR, Galletti PM (1988) Transplantation of neural tissue in polymer capsules. Brain Res 364–368Google Scholar
  2. Agnati L, Fuxe K, Calza L, et al (1983) Gangliosides increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function instriatum of rats by collateral sprouting. Acta Physiol Scand 119: 347–363Google Scholar
  3. Albin RL, Greenamyre JT (1992) Alternative excitotoxic hypotheses. Neurology 42: 733–738Google Scholar
  4. Albin RL, Young Ab, Penney JB, et al (1990) Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 322: 1293–1298Google Scholar
  5. Arends MJ, Morris RG, Wyllie AH (1990) Apoptosis — the role of the endonuclease. Am J Pathol 136: 593–608Google Scholar
  6. Aust FD, White BC (1985) Iron chelation prevents tissue injury following ischemia. Adv Free Rad Biol Med 1: 1–17Google Scholar
  7. Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31: 119–130Google Scholar
  8. Beal MF, Kowall NW, Elisson DW, et al (1986) Replication of the neurochemical eharacteristics of Huntington's disease by quinolinic acid. Nature 321: 168–171Google Scholar
  9. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW (1991) Chronic quinolinic acid lesions in rats closely mimic Huntington's disease. J Neurosci 11: 1649–1659Google Scholar
  10. Beal MF, Schartz KJ, Hyman BT, et al (1991) Aminooxyacetic acid results in excitotoxic lesions by a novel indirect mechanism. J Neurochem 57: 1068–1073Google Scholar
  11. Beckman JS, Beckman TW, Chen J, et al (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620–1624Google Scholar
  12. Bellomo G, Perotti M, Taddei F, et al (1992) Tumor necrosis factor a induces apoptosis in mammary adenocarcinoma cell by an increase in intranuclear free Ca2+ concentration and DNA fragmentation. Cancer Res (in press)Google Scholar
  13. Ben-Shachar D, Eshel G, Finberg JPM, Youdim M (1991) The iron chelator desferrioxamine (desferal) retards 6-hydroxy dopamine-induced degeneration of nigral striatal dopamine neurons. J Neurochem 56: 1441–1444Google Scholar
  14. Bernsen PLJA, Gabreels FJM, Ruitenbeek W, et al (1991) Successful treatment of pure myopathy, associated with complex I deficiency with riboflavin and carnitine. Arch Neurol 48: 334–338Google Scholar
  15. Birkmayer W, Knoll J, Riederer P, Youdim M, etal (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 64: 113–127Google Scholar
  16. Blake DR, Winyard P, Lonec J, et al (1985) Cerebral and occular toxicity induced by desferioxamine. Q J Med 219: 345–355Google Scholar
  17. Bodis-Wollner I, Chung E, Chilardi MF, Glover A, Onofrj M, Pasik P, Samson Y (1991) Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J Neural Transm [PD Sect] 3: 63–72Google Scholar
  18. Bohn MC, Cupit L, Marciana F, et al (1987) Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers. Science 237: 913–915Google Scholar
  19. Braughler JM, Pregenzer JF, Chase RL, Duncan LA, Jacobsen EJ, McCall JM (1987) Novel 21-aminosteroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem 262: 10438–10440Google Scholar
  20. Burkitt MJ, Fichett M, Gilberg BC (1988) Free radical damage to nucleic acid components initiated by the Fenton reaction: an E.S.R. study. In: Hayaishi O, Niki E, Kondo M (eds) Medical biochemical and chemical aspects of free radicals. Elsevier, Amsterdam, pp 63–70Google Scholar
  21. Burton GW, Ingold KU (1984) B-carotene: an unusual type of lipid antioxidant. Science 224: 569–573Google Scholar
  22. Calne DB, Langston JW (1983) Aetiology of Parkinson's disease. Lancet ii: 1457–1459Google Scholar
  23. Cantoni O, Sestili O, Catabeni F, et al (1990) Calcium chelator Quin 2 prevents hydrogenperoxide-induced DNA breakage and cytotoxicity. Eur J Biochem 182: 209–212Google Scholar
  24. Carafoli E (1989) Intracellular Ca2+ homeostasis. Annu Rev Biochem 56: 395–433Google Scholar
  25. Carafoli E (1991) Calcium pump of the plasma membrane. Physiol Rev 71: 129–153Google Scholar
  26. Chan P, DeLanney LE, Irwin I, et al (1991) Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mourse brain. J Neurochem 57: 348–351Google Scholar
  27. Chiamulera C, Costa S, Reggiani A (1990) Effects of NMDA and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning. Psychopharmacology 102: 551–552Google Scholar
  28. Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 547–578Google Scholar
  29. Choi DW (1988) Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 11: 465–469Google Scholar
  30. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623–634Google Scholar
  31. Choi DW (1990) Cerebral hypoxia: some new approaches and unanswered questions. J Neurosci 10: 2493–2501Google Scholar
  32. Choi DW (1990) Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev 2: 105–147Google Scholar
  33. Cochrane CJ, Schraufstatter I, Hyslop P, Jackson J (1988) Cellular and biochemical events in oxidant injury. In: Halliwell B (ed) Oxygen radicals and tissue injury. FASEB: 49–54Google Scholar
  34. Cohen G, Pasik P, Cohen B, et al (1985) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106: 209–210Google Scholar
  35. Coyle JT, Schwarcz R (1976) Lesions of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature 263: 244–246Google Scholar
  36. Date I, Notter MFD, Felten SY, Felten DL (1990) MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF). Brain Res 526: 156–160Google Scholar
  37. Dawson VL, Dawson TM, London ED, et al (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical culture. Proc Natl Acad Sci USA 88: 6368–6371Google Scholar
  38. Dawson TM, Dawson VL, Snyder SH (1992) A novel neuronal messenger molecule in brain: the free radical, nitric oxide. Ann Neurol 32: 297–311Google Scholar
  39. Dexter DT, Carter CJ, Wells FR, et al (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381–389Google Scholar
  40. Dexter DT, Wells FR, Lees AJ, et al (1989) Increased nigral iron content and alterations in other metal iron occuring in brain in Parkinson's disease. J Neurochem 52: 1830–1836Google Scholar
  41. During MJ, Geller AI, Deutch AY, Neve RL, O'Malley KL (1991) Expression of human tyrosine hydroxylase and unregulated signal transduction enzymes in neurons in the mammalian brain, from HSV-1 vectors. Soc Neurosci Abstr 17: 56.8Google Scholar
  42. Dypbukt JM, Thor H, Nicotera P (1990) Intracellular Ca2+ chelators prevent DNA damage and protect hepatoma 1c1c7 cells from quinone-induced cell killing. Free Radic Res Commun 8: 347–354Google Scholar
  43. Ferrari G, Minozzi MC, Toffano G, Leon A, Skaper SD (1989) Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture. Dev Biol 133: 140–147Google Scholar
  44. Floyd RA (1990) Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB 4: 2587–2597Google Scholar
  45. Frei B, England L, Ames BN (1989) Ascorbate is an out-standing antioxidant in human blood plasma. Proc Natl Acad Sci USA 86: 6377–6381Google Scholar
  46. Gage FH (1990) Intracerebral grafting of genetically modified cells acting as biological pumps. Trends Pharmacol Sci II: 437–439Google Scholar
  47. Gelmers HJ, Gorter K, DeWeerdt CJ, Wiezer HJA (1988) A controlled trial of nimodopine in acute ischemic stroke. N Engl J Med 318: 203–207Google Scholar
  48. Glover V, Sandier M, Owen F, Riley GJ (1977) Dopamine is a monoamine B substrate in man. Nature 265: 80–81Google Scholar
  49. Good PF, Olanow CW, Perl DP (1992) Neuromelanin containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease. A LAMMA study. Brain Res (in press)Google Scholar
  50. Granger DL, Lehninger AL (1982) Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells. J Cell Biol 95: 527–535Google Scholar
  51. Hadjiconstantinou M, Mariani AP, Neff NH (1989) GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study. Brain Res 484: 297–303Google Scholar
  52. Halliwell B (1989) Protection against tissue damage in vivo by deferrioxamine. What is its mechanism of action? Free Radic Biol Med 7(6): 645–651Google Scholar
  53. Halliwell B, Gutteridge JMC (1985) Oxygen radicals and the nervous system. TINS 8: 22–29Google Scholar
  54. Halliwell B, Gutteridge JMC (1988) Iron as a biological pro-oxidant. ISI Atlas Sci Biochem 1: 48–52Google Scholar
  55. Hamburger V, Levi-Montalcini R (1949) Proliteration, differentiation and degeneration in the spinal ganglia of the chick embryo under normal and experimental conditions. J Exp Zool 111: 457–502Google Scholar
  56. Hefti F (1986) Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transection. J Neurosci 6: 2155–2162Google Scholar
  57. Heikkila RE, Nicklas WJ, Vyas I, Duvoisin RC (1985) Dopaminergic toxicity of rotenone and the MPP ion after their stereotaxic administration to rats: implications for the mechanism of MPTP toxicity. Neurosci Lett 682: 389–394Google Scholar
  58. Helgren ME, Wong V, Kennedy M, et al (1992) Ciliary neurotrophic factor (CNTF) slows the progression of motor dysfunction in the Mnd mouse. Neurology 42(3)Google Scholar
  59. Holmlund TH, Mitsomoto H, Greene T, et al (1992) The effect of ciliary neurotrophic factor (CNTF) on spontaneously degenerating motor neurons in Wobbler mice. Neurology 42(3): 369Google Scholar
  60. Hyman C, Hofer M, Barde Y, et al (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350: 230–232Google Scholar
  61. Ihara Y, Namba R, Kuroda S, et al (1989) Mitochondrial encephalopathy (MELAS): pathological study and successful therapy with coenzyme Q 10 and idebenone. J Neurol Sci 90: 263–271Google Scholar
  62. Ikebe S, Tankaka M, Ohno K, et al (1990) Increase of deleted mitochondria DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 170: 1044–1048Google Scholar
  63. Ingold KU, Webb AC, Witter D, et al (1987) Vitamin E remains the major lipid-soluable, chain-breaking antioxidant in human plasma even in individuals suffering severe vitamin E deficiency. Arch Biochem Biophys 259: 224–225Google Scholar
  64. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MBH (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59: 1168–1171Google Scholar
  65. Jewelll SA, Bellomo G, Thor H, et al (1982) Bleb formation in hepatocytes during drug metabolism is caused by disturbances in thiol and calcium ion hemeostasis. Science 217: 1257–1259Google Scholar
  66. Jones DP, McConkey DJ, Nicotera P, Orrenius S (1989) Calcium-activated DNA fragmentation in rat liver nuclei. J Biol Chem 264: 6398–6403Google Scholar
  67. Kanner BI, Schuldliner S (1987) Mechanism of transport and storage of neurotransmitters. CRC Crit Rev Biochem 22: 1–18Google Scholar
  68. Keinanen K, Wisden W, Sommer B, et al (1990) A family of AMPA-selective glutamate receptors. Science 249: 556–560Google Scholar
  69. Kindt MV, Youngster SK, Sonsalla PK, et al (1988) Role for the monoamine oxidase A (MAO-A) in the bioactivation and nigral striatal dopaminergic neurotoxicity of the MPTP analog 2'ME-MPTP. Eur J Pharmacol 146: 313–318Google Scholar
  70. Klockgether T, Turski L (1990) NMDA antagonist potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 28: 539–546Google Scholar
  71. Koek W, Colpaert C (1990) Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencylidine-like behavioral effects. J Pharmacol Exp Ther 252: 349–357Google Scholar
  72. Kordower JH, Fiandaca MS, Notter MFD, et al (1990) Peripheral nerve provides NFG-like trophic support for grafted Rhesus adrenal chromaffin cells. J Neurosurg 73: 418–428Google Scholar
  73. Kordower JH, Cochran E, Penn R, et al (1991) Putative chromaffin cell survival and enhanced host derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson's disease. Ann Neurol 29: 405–412Google Scholar
  74. Längsten JW, Irwin I, Langston EB, Forno LS (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225: 1480–1482Google Scholar
  75. Linnane Aw, Baumer A, Maxwell RJ, et al (1990) Mitochondrial gene mutation: the aging process and degenerative diseases. Biochem Int 22: 1067–1076Google Scholar
  76. Lucas DR, Newhouse JP (1957) The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch Opthalmol 58: 193–201Google Scholar
  77. Mann DMA, Yates PO (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Aging Dev 21: 193–203Google Scholar
  78. Maragos WF, Greenamyre JT, Penny JB, Young AB (1987) Glutamate dysfunction in Alzheimer's disease: an hypothesis. Trends Neurosci 10: 65–68Google Scholar
  79. McGeer EG, McGeer PL (1976) Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263: 517–519Google Scholar
  80. Mirabelli F, Salis A, Vairetti M, et al (1989) Cytoskeletal alterations in human platelets exposed to oxidative stress are mediated by oxidative and Ca2+-dependent mechanisms. Arch Biochem Biophys 270: 478–488Google Scholar
  81. Mizuno Y, Ohta S, Tanaka M, et al (1989) Deficiences in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163: 1450–1455Google Scholar
  82. Monaghan DT, Olverman HJ, Nguyen L, et al (1988) Two classes of N-methyl-D-aspartate recognition sites: differential distribution and differential regulation by glycine. Proc Natl Acad Sci USA 85: 9836–9840Google Scholar
  83. Monaghan DT, Bridges RJ, Cotman CW (1989) The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29: 365–402Google Scholar
  84. Moncada S, Palmer RMJ, Higgs EA (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109–142Google Scholar
  85. Nicholls D, Attwell D (1990) The release and uptake of excitatory amino acids. Trends Pharmacol Sci 11: 462–468Google Scholar
  86. Nicotera P, McConkey DJ, Jones DP, Orrenius S (1989) ÁTP stimulated Ca2+ uptake and increases the free Ca2+ concentration in isolated rate liver nuclei. Proc Natl Acad Sci USA 86: 453–457Google Scholar
  87. Nicotera P, Bellomo G, Orrenius S (1990) The role of Ca2+ in cell killing. Chem Res Toxicol 3: 484–494Google Scholar
  88. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451: 205–212Google Scholar
  89. Olanow CW (1990) Oxidation reactions in Parkinson's disease. Neurology 40: 32–37Google Scholar
  90. Olanow CW (1992) Protective therapy for Parkinson's disease. In: Olanow CW, Leiberman A (eds) The scientific basis for the treatment of Parkinson's disease. Parthenon Publishing, London, pp 225–256Google Scholar
  91. Olanow CW, Calne D (1992) Does deprenyl monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 42(4): 13–36Google Scholar
  92. Olney JW (1969) Brain lesion, obesity and other disturbances in mice treated with monosodium glutamate. Science 164: 719–721Google Scholar
  93. Olson L, Backlund E, Ebendal T, et al (1991) Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease: one year follow-up of first clinical trial. Arch Neurol 48: 373–381Google Scholar
  94. Orrenius S, Burkitt MJ, Kass GEN, Dypbukt JM, Nicotera P (1992) Calcium ions and oxidative cell injury. Ann Neurol (in press)Google Scholar
  95. Otto D, Unsicker K (1990) Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J Neurosci 10: 1912–1921Google Scholar
  96. Parker WD, Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719–723Google Scholar
  97. Pellegrini-Giampietro DE, Cherichi G, Alesiani M, Carla V, Moroni F (1988) Excitatory amino acid release from rat hippocampal slices as a consequence of free-radical formation. J Neurochem 51: 1961–1963Google Scholar
  98. Perry TL, Godin DV, Hansen S (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neuroscience 33: 305–310Google Scholar
  99. Plaitakis A (1982) The olivopontocerebellar atrophies. Semin Neurol 2: 334–342Google Scholar
  100. Plaitakis A (1990) Glutamate dysfunction and selective motor neurons degeneration in amyotrophic lateral sclerosis: a hypothesis. Ann Neurol 28: 3–8Google Scholar
  101. Przyrembel H (1987) Therapy of mitochondrial disorders. J Inherited Metab Dis 10: 129–146Google Scholar
  102. Ramsey RR, Krueger MJ, Youngster Sk, et al (1991) Interaction of 1-methyi-4-phenyl-pyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J Neurochem 56: 1184–1190Google Scholar
  103. Richter C, Park J-W, Ames BN (1988) Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 85: 6465–6467Google Scholar
  104. Sadrzadeh SM, Eaton JW (1988) Hemoglobin-mediated oxidant damage to the central nervous system requires endogenous ascorbate. J Clin Invest 82: 1510–1515Google Scholar
  105. Schapira AHV, Cooper JM, Detter D, et al (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823–827Google Scholar
  106. Schneider JS, Yuwiler A (1989) GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism. Exp Neurol 105: 177–183Google Scholar
  107. Schneider JS, Pope A, Simpson K, et al (1992) Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 256: 843–846Google Scholar
  108. Schwarcz R, Whetsell WO, Mangano RM (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219: 316–318Google Scholar
  109. Sendtner M, Kreutzberg GW, Thoenen H (1990) Ciliary neurotrophic factor prevents the degeneration of motor neurons after axomotomy. Nature 345: 440–441Google Scholar
  110. Sengstock GJ, Olanow CW, Dunn AJ, et al (1992) Iron induces degeneration of substantia nigra neurons. Brain Res Bull 28: 645–649Google Scholar
  111. Sheardown MJ, Nielson EO, Hansen AJ, Jacobsen P, Honore T (1990) 2,3-D,hydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 247: 571–574Google Scholar
  112. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC (1991) Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 30: 332–339Google Scholar
  113. Somylo AP, Bond M, Somylo AV (1985) Calcium content of mitochondria and endoplasmic reticulum in liver frozen rapidly in vivo. Nature 14: 622–625Google Scholar
  114. Sonsalla PK, Nicklas WJ, Heikkila RE (1989) Role of excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243: 394–400Google Scholar
  115. Spencer PS, Ludolph AC, Divivedi MP, et al (1986) Lathyrism: evidence for role of neuroexcitatory amino acid BOAA. Lancet ii: 1066–1067Google Scholar
  116. Stockli KA, Lottspeich F, Sendtner M, et al (1989) Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor. Nature 342: 920–923Google Scholar
  117. Stromberg I, Herrera-Marschitz M, Ungerstedt U, et al (1985) Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behavior. Exp Brain Res 60: 335–349Google Scholar
  118. Tetrud JW, Langston JW (1989) The effect of Deprenyl (Selegiline) on the natural history of Parkinson's disease. Science 245: 519–522Google Scholar
  119. The Parkinson's Study Group (1989) Effect of Deprenyl on the progression of disability in early Parkinson's disease. NEJM 321: 1364–1371Google Scholar
  120. The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176–183Google Scholar
  121. Turski L, Bressler K, Retting K-J, Loeschmann P-A, Eachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349: 414–418Google Scholar
  122. Tsien RW, Tsien RY (1990) Ca2+ channels, stores and oscillations. Annu Rev Cell Biol 6: 715–760Google Scholar
  123. Watkins JC, Evans RJ (1981) Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol 21: 165–204Google Scholar
  124. Westermann R, Johannsen M, Unsicker K, Grothe C (1990) Basic fibroblast growth factor (bFGF) immunoreactivity is present in chromaffin granules. J Neurochem 55: 282–292Google Scholar
  125. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230: 181–183Google Scholar
  126. Williams LR, Varon S, Peterson GM, et al (1986) Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci USA 83: 9231–9235Google Scholar
  127. Yamada T, McGeer PL, Baimbridge KG, McGeer EG (1990) Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28 k. Brain Res 526: 303–307Google Scholar
  128. Young Ab, Greenamyre JT, Hollingsworth Z, et al (1988) NMDA receptor losses in putamen from patients with Huntington's disease. Science 241: 981–983Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • C. W. Olanow
    • 1
  1. 1.Department of NeurologyUniversity of South FloridaTampaUSA

Personalised recommendations